Abstract
Diabetes mellitus is one of the most costly and burdensome chronic disease of our time. Diabetes mellitus is a metabolic disorder characterized by hyperglycemia due to resistance to the action of insulin, insufficient insulin secretion, or both. Diabetes mellitus causes nephropathy and fatty change in the liver and vascular changes. Rosiglitazone and repaglinide are new anti-diabetic agents. Rosiglitazone is a thiazolidinedione's agent acting as insulin-sensitizer. Repaglinide a non-sulphonyl urea insulin secretagogue, is a prandial glucose regulator. The present study is aimed to assess the potential protective role of Rosiglitazone and Repaglinide on Liver and Kidney tissues of diabetic guinea pig (Caviaporcellus). The used Guinea pigs were divided into five groups. Diabetes mellitus is induced in 4 groups of them by oral administration of fructose 50% concentration. One of the diabetic groups was served as diabetic non treated and the other 3 groups were treated by Rosiglitazone, Repaglinide and a combination of both drugs, respectively. Blood samples were collected for the biochemical studies. The animals were sacrificed and the liver and kidney were excised to be used for the histopathological studies. The present study showed that, the combination of rosiglitazone & repaglinide may have a synergistic protective effect against diabetes mellitus - induced renal and liver tissues damage. This study proved that the combination of rosiglitazone &repaglinide in treatment of diabetes mellitus is better than rosiglitazone or repaglinidealone in protection of the Liver and Kidney tissues of diabetic Guinea pigs, Caviaporcellus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
